These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 15238990)
1. Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Hofheinz RD; Hartmann JT; Willer A; Oechsle K; Hartung G; Gnad U; Saussele S; Kreil S; Bokemeyer C; Hehlmann R; Hochhaus A Br J Cancer; 2004 Aug; 91(5):834-8. PubMed ID: 15238990 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. Ernst T; Merx K; Gnad-Vogt U; Lukan N; Kripp M; Schultheis B; Hochhaus A; Hofheinz RD Br J Cancer; 2007 Dec; 97(11):1475-9. PubMed ID: 18000507 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Rao S; Cunningham D; Price T; Hill ME; Ross PJ; Tebbutt N; Norman AR; Oates J; Shellito P Br J Cancer; 2004 Aug; 91(5):839-43. PubMed ID: 15266319 [TBL] [Abstract][Full Text] [Related]
4. A phase I dose escalation study of a pharmacobiologically based scheduling of capecitabine and mitomycin C in patients with gastrointestinal malignancies. Bekaii-Saab T; Hill M; Campbell A; Kosuri K; Thomas J; Villalona-Calero M Cancer Chemother Pharmacol; 2010 Apr; 65(5):863-9. PubMed ID: 19657639 [TBL] [Abstract][Full Text] [Related]
5. Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G Anticancer Res; 2013 Jun; 33(6):2743-6. PubMed ID: 23749935 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. Kruth J; Nissen J; Ernst T; Kripp M; Lukan N; Merx K; Hofmann WK; Hochhaus A; Hofheinz RD J Cancer Res Clin Oncol; 2010 Dec; 136(12):1845-51. PubMed ID: 20224968 [TBL] [Abstract][Full Text] [Related]
7. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990 [TBL] [Abstract][Full Text] [Related]
8. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808 [TBL] [Abstract][Full Text] [Related]
10. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353 [TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026 [TBL] [Abstract][Full Text] [Related]
14. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. O'connor T; Rustum Y; Levine E; Creaven P Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498 [TBL] [Abstract][Full Text] [Related]
16. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
17. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Nolè F; Catania C; Munzone E; Rocca A; Verri E; Sanna G; Ascione G; Adamoli L; Zampino MG; Minchella I; Goldhirsch A Clin Breast Cancer; 2006 Feb; 6(6):518-24. PubMed ID: 16595035 [TBL] [Abstract][Full Text] [Related]
18. [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma]. Guo L; Lin HX; Li FY; Li Q; Qiu F; Luo DH; Guo X; Hong MH Zhonghua Zhong Liu Za Zhi; 2004 Apr; 26(4):250-3. PubMed ID: 15312392 [TBL] [Abstract][Full Text] [Related]
19. Mitomycin C and capecitabine combination (MiXe) in heavily pretreated metastatic breast cancer patients. A dose-finding study. Maisano R; Caristi N; Mare M; Mafodda A; Carboni R; Montalto E; Iorfida M; Nardi M Anticancer Res; 2005; 25(6C):4513-7. PubMed ID: 16334135 [TBL] [Abstract][Full Text] [Related]
20. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]